|
|
T-vant |
|
Vaxjo ID |
201 |
|
Vaccine Adjuvant Name |
T-vant |
|
Adjuvant VO ID |
VO_0005375
|
|
Description |
A vaccine adjuant that is derived from Salmonella enterica serovar typhimurium and is able to induce Th1/Th2/Th17 immune responses through the mechanism of action of TLR4, inflammasome, and DC activation |
|
Stage of Development |
Research |
|
Location Licensed |
US (Tulane University) |
|
Host Species for Testing |
3 |
|
Components |
B. pseudomallei strain Bp82 or S. Typhimurium |
|
Storage |
-20 or -80C |
|
Preparation |
bacterial culture diluted into LB and incubated then centrifuged. Precipitation by incubating with ammonium sulfate and then harvested by centrifugation |
|
Function |
TLR4; inflammasome; DC activation |
| References |
(Morici, 2022): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=61]
Harrell et al., 2021: Harrell JE, Kurtz JR, Bauer DL, Prior JT, Gellings PS, Morici LA, McLachlan JB. An Outer Membrane Vesicle-Adjuvanted Oral Vaccine Protects Against Lethal, Oral Salmonella Infection. Pathogens (Basel, Switzerland). 2021; 10(5); . [PubMed: 34069796].
Prior et al., 2021: Prior JT, Davitt C, Kurtz J, Gellings P, McLachlan JB, Morici LA. Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses. Pharmaceutics. 2021; 13(2); . [PubMed: 33498352].
|
|
